A potential new strategy to slow the relentless march of alzheimer’s disease has emerged from laboratory research, offering a glimmer of hope for the more than 55 million people worldwide living with dementia. A new study reveals a surprising link between an enzyme and the brain’s ability to clear the toxic protein buildup characteristic of the disease.
Unlocking the Brain’s Cleanup Crew: A New Alzheimer’s Target
Table of Contents
Scientists have identified an enzyme that appears to hinder the brain’s natural defenses against Alzheimer’s, potentially opening a new avenue for treatment.
- Researchers at Cold Spring Harbor Laboratory found that the enzyme PTP1B contributes to memory decline in mice with Alzheimer’s.
- Blocking PTP1B activity helped the brain’s immune cells,called microglia,clear amyloid-β plaques.
- PTP1B also plays a role in metabolic conditions like obesity and type 2 diabetes, which are risk factors for Alzheimer’s.
the study, published in the journal nature Neuroscience, was led by Yuxin Cen and overseen by Dr. Tonks, the study’s corresponding author and a professor at the lab.
The team discovered that reducing PTP1B activity aided the brain’s immune cells – microglia – in removing amyloid-β (Aβ) plaques, the protein clumps strongly associated with Alzheimer’s.Microglia typically act as the brain’s cleanup crew, but their effectiveness diminishes as the disease progresses. “Over the course of the disease, these cells become tired and less effective,” explained Yuxin Cen, the study lead.
Beyond Alzheimer’s: PTP1B’s wider Impact
Interestingly, PTP1B isn’t solely implicated in neurodegenerative diseases. it’s already known to play a notable role in metabolic conditions like obesity and type 2 diabetes,both recognized risk factors for Alzheimer’s disease,according to research published on January 22,2025.
A New Pathway for Treatment
The laboratory is actively developing PTP1B inhibitors for a range of applications. for Alzheimer’s specifically, Tonks envisions a combined therapeutic approach, integrating PTP1B inhibitors with existing approved medications.
The World health Association currently recommends cholinesterase inhibitors, such as donepezil, for treating Alzheimer’s. NMDA receptor antagonists, like memantine, are prescribed for more advanced stages of the disease. “The goal is to slow Alzheimer’s progression and improve the quality of life of the patients,” Tonks stated.
Alzheimer’s disease accounts for up to 70 percent of all dementia cases, impacting more than 55 million people globally, according to the WHO. Tonks, who experienced the devastating effects of Alzheimer’s firsthand with his mother, poignantly described the disease as “a slow bereavement. You lose the person piece by piece.”
